Clinical Trial
Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate Cancer
- NCT ID
- NCT06835725
- Status
- Recruiting
- Study Type
- Interventional
- Lead Sponsor
- British Columbia Cancer Agency
- Enrollment
- 100 participants
- Start
- Sep 2025
- Estimated Completion
- Apr 2033
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans
Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.
© 2026 Health AI Central. All rights reserved.
Source: https://healthaicentral.com/research/science-discovery/trials/NCT06835725